A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasisLin Cai, Jianzhong Zhang, Jinyan Wang et al.|British Journal of Dermatology|2024Cited by 21
Identity-by-Descent Analysis Reveals Susceptibility Loci for Severe Acne in Chinese Han CohortXingyan Yang, Ya‐Ping Zhang, Wenjuan Wu et al.|Journal of Investigative Dermatology|2019Cited by 11